Home / Conditions / Heart Attack
Heart Attack: when insurers say no, reviewers often say yes
In 42 published external-review decisions involving heart attack, independent physician reviewers overturned the insurer’s denial 40.5% of the time.
Published decisions
42
2001–2026
Overturned
40.5%
17 denials reversed
Most-fought treatments for heart attack
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Wearable Cardio Defib | 6 | 83.3% |
| Cardiac Rx | 5 | 60% |
| CT Scan | 3 | 0% |
| Emergency Room | 3 | 66.7% |
| Inpt Admission | 3 | 0% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 23 | 30.4% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 16 | 50% |
Urgent Care Expedited reviews, decided in days rather than weeks. | 3 | 66.7% |
Typical time to a decision
20 days
Most land between 13 and 22 days
Handled as urgent
33.3%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: A 50-year-old female enrollee has requested reimbursement for the Zoll LifeVest wearable cardioverter defibrillator.The American College of Cardiology (ACC) and American Heart Association (AHA) guidelines note that patients with recent myocardial infarction, newly diagnosed nonischemic cardiomyopathy, recent revascularization, myocarditis, and secondary cardiomyopathy are at increased risk of sudden cardiac arrest. Patients who may benefit from automatic emergency cardioversion-defibrillation but do not meet indications for ICD implantation at the time of presentation include those who are at perceived increased risk of sudden cardiac death due to severe left ventricle dysfunction but for whom there may be optimism for clinical improvement, and those who have a clear indication for ICD but who have a contraindication to immediate placement.
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for services provided. Findings: The physician reviewer found that The patient has a history of smoking, anxiety and hyperlipidemia. The patient presented to the emergency department on the day of dispute with chest discomfort for a few weeks associated with dyspnea and diaphoresis. The patient was subsequently ruled in for a non-ST-elevation segment elevation myocardial infarction (NSTEMI). The patient was treated with Lovenox and Integrilin. Cardiac catheterization performed and reported a left ventricular ejection fraction of 20% and a stent was placed to the left anterior descending coronary artery that was described to have a spontaneous dissection and thrombus. A LifeVest was placed and the patient was discharged.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for intravascular optical coherence tomography for evaluation of the enrollee who presented with chest tightness. Findings: 2/3 of the physician reviewers found that while the research in intravascular optical coherence tomography (OCT) for assessing coronary artery disease has advanced over last several years, it has not been proven with any long term study or trial that it is better than other standard available options. OCT is a high resolution catheter based imaging modality that helps visualization of coronary artery disease. It has potential applications including coronary artery lesion assessment, as an adjunct to percutaneous coronary intervention (PCI) in treatment of these lesions and follow up evaluation after coronary stent placement.
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for a wearable cardioverter defibrillator for three months. The wearable cardioverter defibrillator is indicated as a temporary therapy for patients with a high risk for sudden cardiac death (SCD). The American College of Cardiology (ACC), American Heart Association (AHA), and Heart Rhythm Society (HRS) guidelines on the management of patients with ventricular arrhythmias note that patients who may benefit from the temporary use of a wearable cardioverter defibrillator include: patients with a permanent implantable cardioverter-defibrillator (ICD) that must be explanted, or those with a delay in implanting a newly indicated ICD; patients with reduced left ventricular (LV) systolic function [a LV ejection fraction (EF) at or less than 35%] who have undergone coronary revascularization with coronary artery b…
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for heart attack was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.